Clinical Trial Update: Methylprednisolone During the Switch Between Natalizumab and Fingolimod [Phase 4]

View source ↗

Summary

Phase 4 clinical trial update on methylprednisolone during the switch from natalizumab to fingolimod in multiple sclerosis patients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• Fingolimod (fingolimod)
• METHYLPREDNISOLONE (methylprednisolone)
• Natalizumab (natalizumab)

Snippet

Sponsor: University Hospital, Clermont-Ferrand | Conditions: Multiple Sclerosis | Phase 4 | Status: UNKNOWN